KIIC member has identified Antibodies Therapeutic solutions as part of its member’s strategic focus area, aiming to invest and drive innovation in this sector.
The business opportunity
For KIIC member: expand knowledge and potentially broaden offerings for the treatment of immune-mediated and fibrotic disorders, including orphan diseases.
For the startup: leverage the member's expertise and geographical distribution through potential future partnerships such as licensing or strategic cooperation.
KIIC conducted industry research and scouting, as well as designed a customized delegation for their member's senior management and investment team. Through connections with key players in the ecosystem, the startup emerged as a highly suitable solution, with a strong team and an impressive list of investors.
The investment was made alongside tier1 global VCs, enhancing the network and investor relations of the KIIC member for future co-investment opportunities
Within six months of the investment, the company merged with a leading Therapeutics company.